Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway

Circulation

Volumn 96, Issue 1, 1997, Pages 326-333

  Collard, Charles D ^a   Väkevä, Antti ^a   Büküsoglu, Cüneyt ^a   Zünd, Gregor ^a   Sperati, C John ^a   Colgan, Sean P ^a   Stahl, Gregory L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Endothelium; Hypoxia; Ischemia; Reperfusion

Indexed keywords

COMPLEMENT COMPONENT C3B; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; REGULATOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPOXIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REOXYGENATION; REPERFUSION INJURY; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

EID: 0342894773     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.1.326     Document Type: Article

References (38)

1. Kilgore KS, Friedrichs GS, Homeister JW, Lucchesi BR. The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc Res. 1994;28:437-444.
2. Lucchesi BR. Complement activation, neutrophils, and oxygen radicals in reperfusion injury. Stroke. 1993;24:41-47.
3. Crawford MH, Grover FL, Kolb WP, McMahan CA, O'Rourke RA, McManus LM, Pinckard RN. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circ Res. 1988;78:1449-1458.
4. Matsuda T, Itoh S, Anderson J. Endothelial injury during extracorporeal circulation: neutrophil-endothelium interaction induced by complement activation. J Biomed Mater Res. 1994;28:1387-1395.
5. Entman ML, Smith CW. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc Res. 1994;28:1301-1311.
6. Homeister JW, Lucchesi BR. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol. 1994;34:17-40.
7. Maroko PR, Carpenter CB, Chariello M. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest. 1978;61:661-670.
8. Pinckard RN, O'Roarke RA, Crawford MH. Complement localization and mediation of ischemic injury in baboon myocardium. J Clin Invest. 1980;66:1050-1056.
9. Weisman HF, Bartow T, Leppo MK, Marsh HCJ, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human complement receptor type I: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990;249:146-151.
10. Mathey D, Schofer J, Schafer H, Hamdoch T, Joachim H, Ritgen A, Hugo F, Bhakdi S. Early accumulation of the terminal complement-complex in the ischemic myocardium after reperfusion. Eur Heart J. 1994;15:418-423.
11. Väkevä A, Morgan BP, Tikkanen I, Helin K, Laurila P, Meri S. Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol. 1994;144: 1357-1368.
12. Schafer H, Mathey D, Hugo F, Bhakdi S. Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol. 1986;137:1945-1949.
13. Rus HG, Niculescu F, Vlaicu R. Presence of C5b-9 complement complex and S-protein in human myocardial areas with necrosis and sclerosis. Immunol Lett. 1987;16:15-20.
14. Hugo F, Hamdoch T, Mathey D, Schafer H, Bhakdi S. Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol. 1990;81:132-136.
15. Vakeva A, Laurila P, Meri S. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest. 1992;67:608-616.
16. Vakeva A, Laurila P, Meri S. Regulation of complement membrane attack complex formation in myocardial infarction. Am J Pathol. 1993;143:65-75.
17. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 1995;91:393-402.
18. Muller-Eberhard HJ. Molecular organization and function of the complement system. Annu Rev Biochem. 1988;57:321-347.
19. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol. 1994;15:369-396.
20. Weiser MR, Williams JP, Moore FD Jr, Kobzik L, Ma MH, Hechtman HB, Carroll MC. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med. 1996;183:2343-2348.
21. Gimbrone MA Jr, Shefton EJ, Cruise SA. Isolation and primary culture of endothelial cells from human umbilical vessels. TCA Manual. 1978;4:813-818.
22. Maciag T, Hover GA, Stemerman MB, Weinstein J. Serial propagation of human endothelial cells in vitro. J Cell Biol. 1981;91: 420-428.
23. Zünd G, Nelson DP, Neufeld EJ, Dzus AL, Bischoff J, Mayer JE, Colgan SP. Hypoxia enhances stimulus-dependent induction of E-selectin on aortic endothelial cells. Proc Natl Acad Sci U S A. 1996;93:7075-7080.
24. LeBivic A, Francisco XR, Rodriquez-Boulan E. Vectorial targeting of apical and basolateral plasma membrane proteins in a human adenocarcinoma epithelial cell line. Proc Natl Acad Sci U S A. 1989; 86:9313-9317.
25. Brooimans RA, Van Wieringen PAM, Van Es LA, Daha MR. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis. Eur J Immunol. 1992;22: 3135-3140.
26. Collard CD, Bukusoglu C, Colgan SP, Morrissey MA, Morgan BP, Frendl G, Stahl GL. Surface expression of complement receptor one (CR1) on human umbilical vein endothelial cells (HUVECs): modulation by endothelial hypoxia. Circulation. 1995;92(suppl I): I-38. Abstract.
27. Cole J, Housley GA, Dykman TR, MacDermott RP, Atkinson JP. Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc Natl Acad Sci U S A. 1986;82:859-864.
28. Vogt W, Hesse D. Activation of the fifth component of human complement by oxygen-derived free radicals, and by methionine oxidizing agents: a comparison. Immunobiology. 1992;184:384-391.
29. Sacks T, Moldow CF, Craddock PR, Bowers TK, Jacob HS. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes: an in vitro model of immune vascular damage. J Clin Invest. 1978;61:1161-1167.
30. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury: role of reactive oxygen metabolites. Dig Dis Sci. 1988;33:6S-15S.
31. Amsterdam EA, Stahl GL, Pan H-L, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 1995;268:H448-H457.
32. Mulligan MS, Yeh CG, Rudolph AR, Ward PA. Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. J Immunol. 1992;148:1479-1485.
33. Rossen RD, Michael LH, Hawkins HK, Youker K, Dreyer WJ, Baughn RE, Entman ML. Cardiolipin-protein complexes and initiation of complement activation after coronary artery occlusion. Circ Res. 1994;75:546-555.
34. Marks RM, Todd RFI, Ward PA. Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. Nature. 1989;339:314-317.
35. Vercellotti GM, Platt JL, Bach FH, Dalmasso AP. Neutrophil adhesion to xenogeneic endothelium via iC3b. J Immunol. 1991; 146:730-734.
36. Tsuji S, Kaji K, Nagasawa S. Activation of the alternative pathway of human complement by apoptotic human umbilical vein endothelial cells. J Biochem (Tokyo). 1994;116:794-800.
37. Kilgore KS, Miller BF, Imlay MM, Warren JS. P-selectin and PAF-dependent neutrophil adhesion to endothelial cells is induced by the membrane attack complex (MAC). FASEB J. 1995;9:A35. Abstract.
38. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994;94:1147-1155.